Shots:
- Hutchmed receives $25M as milestones at 1st commercial sales of Orpathys in China & will receive fixed royalties of 30% based on all sales under the license agreement with AstraZeneca
- As per collaboration, Hutchmed is responsible for the clinical development, approvals, manufacturing & supply of Orpathys in China while AstraZeneca is responsible for its commercialization
- Orpathys (PO) is a potent & highly selective MET tyrosine kinase inhibitor, marketed in China for NSCLC with MET exon 14 skipping alterations who have progressed under prior systemic therapy or unable to receive CT & is currently under development as a monothx. & as combination therapy for multiple tumor types
Click here to read full press release/ article | Ref: Globe Newswire | Image: Hutchmed
The post Hutchmed Reports First Commercial Sale of Orpathys (savolitinib) in China first appeared on PharmaShots.
